SIBN SI-BONE, Inc.
Data as of close
Healthcare · Surgical & Medical Instruments & Apparatus
SI-BONE, Inc. (SIBN) is a healthcare company in the Surgical & Medical Instruments & Apparatus industry, with a market capitalization of $1.1 billion. Shares last traded at $24.92, 3.8% below their 52-week high. Over the past year the stock is up 65.5%. Net profit margin is -6.2%, above the peer median of -6.3%. Revenue grew 20.2% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q3 2026 | -$0.08 | 2026-11-03 |
| Q2 2026 | -$0.09 | 2026-08-04 |
| Q1 2026 | -$0.10 | 2026-05-11 |
| Q4 2025 (derived) | -$0.04 | 2026-02-24 |
| FY 2025 | -$0.44 | 2026-02-24 |
| Q3 2025 | -$0.11 | 2025-11-10 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Surgical & Medical Instruments & Apparatus peers
SIBN vs 14 industry peers (Surgical & Medical Instruments & Apparatus), by market cap. Data as of close
| SYK | Stryker Corporation | $129.3B | 35.70 | 4.92 | 13.8% | +9.39% |
| MMM | 3M | $100.2B | 28.35 | 3.97 | 14.0% | +9.58% |
| BSX | Boston Scientific | $66.4B | 19.01 | 3.15 | 16.6% | +5.33% |
| BDX | Becton Dickinson | $57.0B | 60.53 | 2.73 | 4.5% | +5.50% |
| MDLN | Medline Inc. | $35.5B | — | 1.25 | 4.1% | +18.40% |
| RMD | ResMed | $33.8B | 21.23 | 5.90 | 27.8% | +5.89% |
| DXCM | DexCom | $33.0B | 33.29 | 6.46 | 19.4% | +6.62% |
| WST | West Pharmaceutical Services | $28.5B | 44.57 | 8.38 | 18.8% | +0.41% |
| SOLV | Solventum | $15.2B | 10.61 | 1.83 | 17.3% | +5.41% |
| GKOS | Glaukos Corp | $14.6B | — | 21.14 | -24.6% | +5.77% |
| BAX | Baxter International | $13.7B | — | 1.18 | -6.2% | +3.96% |
| PEN | Penumbra Inc | $12.7B | 80.95 | 9.06 | 12.7% | +0.77% |
| GMED | Globus Medical Inc | $11.7B | 21.84 | 3.72 | 17.0% | +9.46% |
| PODD | Insulet Corporation | $11.4B | 26.68 | 3.59 | 13.4% | +6.51% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.